Product Pathways - Chromatin Regulation / Epigenetics
CHD2 Antibody #4170
|4170S||100 µl (10 western blots)||---||In Stock||---|
|4170||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
|W||1:1000||Human, Mouse, Rat, Monkey||Endogenous||260||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Specificity / Sensitivity
This antibody detects endogenous levels of total CHD2 protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Phe1579 of human CHD2 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Chromodomain-helicase-DNA-binding domain (CHD) proteins have been identified in a variety of organisms (1,2). This family of proteins, which consists of nine members, has been divided into three separate subfamilies: subfamily I (CHD1 and CHD2), subfamily II (CHD3 and CHD4), and subfamily III (CHD5, CHD6, CHD7, CHD8, and CHD9). All of the CHD proteins contain two tandem N-terminal chromodomains, a SWI/SNF-related ATPase domain, and a C-terminal DNA binding domain (1,2). The chromodomains facilitate binding to methylated lysine residues of histone proteins and confer interactions with specific regions of chromatin. The SWI/SNF-related ATPase domain utilizes the energy from ATP hydrolysis to modify chromatin structure. CHD1 is a euchromatic protein that associates with the promoters of active genes, and is required for the maintenance of open chromatin and pluripotency in embryonic stem cells (3-6). The two chromodomains of CHD1 facilitate its recruitment to active genes by binding to methyl-lysine 4 of histone H3, a mark associated with transcriptional activation (4-6). Yeast CHD1 is a component of the SAGA and SLIK histone acetyltransferase complexes, and is believed to link histone methylation with histone acetylation during transcriptional activation (6). The CHD2 protein is not well characterized; however, mouse knockout studies suggest important functions in development and tumor suppression. Homozygous CHD2 knockout mice exhibit delayed growth and perinatal lethality (7). Heterozygous knockout mice show increased mortality and gross organ abnormalities, in addition to increased extramedullary hematopoiesis and susceptibility to lymphomas (7,8). CHD2 mutant cells are defective in hematopoietic stem cell differentiation and exhibit aberrant DNA damage responses (8).
- Hall, J.A. and Georgel, P.T. (2007) Biochem Cell Biol 85, 463-76.
- Marfella, C.G. and Imbalzano, A.N. (2007) Mutat Res 618, 30-40.
- Gaspar-Maia, A. et al. (2009) Nature 460, 863-8.
- Sims, R.J. et al. (2005) J Biol Chem 280, 41789-92.
- Flanagan, J.F. et al. (2005) Nature 438, 1181-5.
- Pray-Grant, M.G. et al. (2005) Nature 433, 434-8.
- Marfella, C.G. et al. (2006) J Cell Physiol 209, 162-71.
- Nagarajan, P. et al. (2009) Oncogene 28, 1053-62.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 4241 CHD3 Antibody
- 4245 CHD4 Antibody
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.